Home > Breast Cancer Information > Facts & Statistics > Research Studies > Research Table Topics > Sacituzumab Govitecan (Trodelvy) for Metastatic Breast Cancer Treatment

Research table: Sacituzumab govitecan (Trodelvy) for metastatic breast cancer treatment

This summary table contains detailed information about research studies. Summary tables are a useful way to look at the science behind many breast cancer guidelines and recommendations. However, to get the most out of the tables, it’s important to understand some key concepts. Learn how to read a research table.

Introduction: Sacituzumab govitecan (Trodelvy) is a Trop-2 antibody-drug conjugate. It combines a Trop-2 antibody and the chemotherapy drug SN-38. This combination allows the targeted delivery of SN-38 to cancer cells that express Trop-2.

Sacituzumab govitecan is used to treat metastatic triple negative breast cancers that have already been treated with at least 2 drug therapies in the metastatic setting. It helps shrink tumors and may improve survival.

Learn more about sacituzumab govitecan, including its side effects.

Study selection criteria: Randomized clinical trials with 200 or more participants with triple negative metastatic breast cancer.

Study

Study Population
(number of participants)

Drug(s) Used

Objective Response Rate—Percent who Responded to Treatment
(95% CI)

Overall Survival
Better with
Sacituzumab Govitecan Compared to Chemotherapy

Randomized clinical trials

TROPiCS-02 study [1]

543

Sacituzumab govitecan alone

20%

Yes

 

 

Chemotherapy alone (eribulin, vinorelbine, capecitabine, or gemcitabine)

14%

 

ASCENT trial [2-3]

529*

Sacituzumab govitecan alone

31%

Yes†

 

 

Chemotherapy alone (eribulin, vinorelbine, capecitabine, or gemcitabine)

4%

 

* 61 of the 529 participants had brain metastases.

† Compared to people who got chemotherapy, people who got sacituzumab govitecan were less likely to die (from breast cancer or other causes), with a hazard ratio of 0.51 (0.41-0.62). Among participants who did not have brain metastases, overall survival at 1 year was 46% among those who got sacituzumab govitecan and 19% among those who got chemotherapy.

References

  1. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 402(10411):1423-1433, 2023.
  2. Bardia A, Rugo HS, Tolaney SM. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol. 2024 Feb 29 [Online ahead of print].
  3. Bardia A, Hurvitz SA, Tolaney SM, et al. for the ASCENT Clinical Trial Investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 384(16):1529-1541, 2021.

Updated 03/13/24